Pharma IQ Members

Vaccines for the World
Contributor: Pharma IQ
Posted: 13/01/2017
Pharma IQ
With several patent expiries in 2015 and 2016, there was high expectation that a significant portion of the biologics market would shift to biosimilar use by 2016, especially in the areas of diabetes, rheumatology, and in tendering markets. I Full Article »
Contributor: Chanice Henry
Posted: 15/03/2016
Miss Chanice Henry
On the route to creating new therapeutics for patients, pharma firms require access a range of diverse biological samples. However, one challenge for the market is locating collaborations that will provide a channel to diverse and high quality samples. This is mirrored by the intentions of both public biobanks and academic or hospital biobanks which have a strong focus on hosting and distributing good quality samples that are of high usability in the eyes of biopharma firms. Full Whitepaper »